These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22139798)

  • 21. Induction of heme oxygenase-1 in vivo suppresses NADPH oxidase derived oxidative stress.
    Datla SR; Dusting GJ; Mori TA; Taylor CJ; Croft KD; Jiang F
    Hypertension; 2007 Oct; 50(4):636-42. PubMed ID: 17679649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
    Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic Myeloid Leukemia with cryptic Philadelphia translocation and extramedullary B-lymphoid blast phase as an initial presentation.
    Soliman DS; Amer AM; Mudawi D; Al-Sabbagh Z; Alkuwari E; Al-Sabbagh A; Ibrahim F; Yassin MA
    Acta Biomed; 2018 Apr; 89(3-S):38-44. PubMed ID: 29633732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment.
    Quintás-Cardama A; Qiu YH; Post SM; Zhang Y; Creighton CJ; Cortes J; Kornblau SM
    Cancer; 2012 Nov; 118(21):5283-92. PubMed ID: 22517119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.
    Liu P; Ma D; Yu Z; Zhe N; Ren M; Wang P; Yu M; Huang J; Fang Q; Wang J
    Biomed Pharmacother; 2017 Jul; 91():21-30. PubMed ID: 28445830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
    J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression.
    Wetzler M; Kurzrock R; Lowe DG; Kantarjian H; Gutterman JU; Talpaz M
    Blood; 1991 Nov; 78(9):2400-6. PubMed ID: 1932751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heme oxygenase-1 reduces the sensitivity to imatinib through nonselective activation of histone deacetylases in chronic myeloid leukemia.
    Wei D; Lu T; Ma D; Yu K; Li X; Chen B; Xiong J; Zhang T; Wang J
    J Cell Physiol; 2019 Apr; 234(4):5252-5263. PubMed ID: 30256411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells.
    Askmyr M; Ågerstam H; Lilljebjörn H; Hansen N; Karlsson C; von Palffy S; Landberg N; Högberg C; Lassen C; Rissler M; Richter J; Ehinger M; Järås M; Fioretos T
    Blood Cancer J; 2014 Dec; 4(12):e269. PubMed ID: 25501026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
    Sorrenti V; Pittalà V; Romeo G; Amata E; Dichiara M; Marrazzo A; Turnaturi R; Prezzavento O; Barbagallo I; Vanella L; Rescifina A; Floresta G; Tibullo D; Di Raimondo F; Intagliata S; Salerno L
    Eur J Med Chem; 2018 Oct; 158():937-950. PubMed ID: 30261468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia.
    Miyazaki K; Yamasaki N; Oda H; Kuwata T; Kanno Y; Miyazaki M; Komeno Y; Kitaura J; Honda Z; Warming S; Jenkins NA; Copeland NG; Kitamura T; Nakamura T; Honda H
    Blood; 2009 May; 113(19):4702-10. PubMed ID: 19234145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
    Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
    Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells.
    Venturini L; Battmer K; Castoldi M; Schultheis B; Hochhaus A; Muckenthaler MU; Ganser A; Eder M; Scherr M
    Blood; 2007 May; 109(10):4399-405. PubMed ID: 17284533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.
    Eiring AM; Neviani P; Santhanam R; Oaks JJ; Chang JS; Notari M; Willis W; Gambacorti-Passerini C; Volinia S; Marcucci G; Caligiuri MA; Leone GW; Perrotti D
    Blood; 2008 Jan; 111(2):816-28. PubMed ID: 17925491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heme oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia.
    Salerno L; Romeo G; Modica MN; Amata E; Sorrenti V; Barbagallo I; Pittalà V
    Eur J Med Chem; 2017 Dec; 142():163-178. PubMed ID: 28756878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. D5 dopamine receptor decreases NADPH oxidase, reactive oxygen species and blood pressure via heme oxygenase-1.
    Lu Q; Yang Y; Villar VA; Asico L; Jones JE; Yu P; Li H; Weinman EJ; Eisner GM; Jose PA
    Hypertens Res; 2013 Aug; 36(8):684-90. PubMed ID: 23425954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of the ETS transcription factor GABPα is positively correlated to the BCR-ABL1/ABL1 ratio in CML patients and affects imatinib sensitivity in vitro.
    Manukjan G; Ripperger T; Santer L; von Neuhoff N; Ganser A; Schambach A; Schlegelberger B; Steinemann D
    Exp Hematol; 2015 Oct; 43(10):880-90. PubMed ID: 26072332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.